Total Payments
$411,140
2024 Payments
$90,949
Companies
4
Transactions
621
Medicare Patients
2,807
Medicare Billing
$214,464
Payment Breakdown by Category
Other$318,880 (77.6%)
Travel$42,063 (10.2%)
Consulting$36,245 (8.8%)
Food & Beverage$13,952 (3.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $318,880 | 151 | 77.6% |
| Travel and Lodging | $42,063 | 240 | 10.2% |
| Consulting Fee | $36,245 | 16 | 8.8% |
| Food and Beverage | $13,952 | 214 | 3.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $294,547 | 454 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $87,151 | 123 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $29,245 | 42 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $196.70 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $90,949 | 118 | Otsuka America Pharmaceutical, Inc. ($45,525) |
| 2023 | $59,342 | 95 | Otsuka America Pharmaceutical, Inc. ($41,627) |
| 2022 | $28,280 | 81 | ACADIA Pharmaceuticals Inc ($28,077) |
| 2021 | $25,761 | 49 | ACADIA Pharmaceuticals Inc ($25,761) |
| 2020 | $9,634 | 9 | ACADIA Pharmaceuticals Inc ($9,634) |
| 2019 | $23,815 | 37 | ACADIA Pharmaceuticals Inc ($23,717) |
| 2018 | $36,656 | 34 | ACADIA Pharmaceuticals Inc ($36,656) |
| 2017 | $136,704 | 198 | ACADIA Pharmaceuticals Inc ($136,704) |
All Payment Transactions
621 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/01/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $13.40 | General |
| Category: PSYCHIATRY | ||||||
| 10/31/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,106.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,975.00 | General |
| Category: Neuropsychiatry | ||||||
| 10/29/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $114.40 | General |
| Category: Neuropsychiatry | ||||||
| 10/24/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,564.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/23/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $121.07 | General |
| Category: PSYCHIATRY | ||||||
| 10/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $201.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $201.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $40.42 | General |
| Category: PSYCHIATRY | ||||||
| 10/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $16.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,975.00 | General |
| Category: Neuropsychiatry | ||||||
| 10/17/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $120.60 | General |
| Category: PSYCHIATRY | ||||||
| 10/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $102.08 | General |
| Category: Neuropsychiatry | ||||||
| 10/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $33.50 | General |
| Category: Neuropsychiatry | ||||||
| 10/14/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $112.87 | General |
| Category: Neuropsychiatry | ||||||
| 10/11/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,078.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/11/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $305.08 | General |
| Category: PSYCHIATRY | ||||||
| 10/08/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $102.80 | General |
| Category: PSYCHIATRY | ||||||
| 10/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $241.20 | General |
| Category: PSYCHIATRY | ||||||
| 09/27/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,078.00 | General |
| Category: PSYCHIATRY | ||||||
| 09/24/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: PSYCHIATRY | ||||||
| 09/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Neuropsychiatry | ||||||
| 09/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $312.80 | General |
| Category: Neuropsychiatry | ||||||
| 09/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $124.35 | General |
| Category: Neuropsychiatry | ||||||
| 09/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $120.60 | General |
| Category: Neuropsychiatry | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 185 | 223 | $6,998 | $2,676 |
| 2022 | 1 | 582 | 2,715 | $85,197 | $53,485 |
| 2021 | 4 | 1,088 | 3,968 | $128,812 | $84,156 |
| 2020 | 4 | 952 | 3,447 | $111,670 | $74,147 |
Total Patients
2,807
Total Services
10,353
Medicare Billing
$214,464
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| Q3014 | Telehealth originating site facility fee | Office | 2023 | 185 | 223 | $6,998 | $2,676 | 38.2% |
| Q3014 | Telehealth originating site facility fee | Office | 2022 | 582 | 2,715 | $85,197 | $53,485 | 62.8% |
| Q3014 | Telehealth originating site facility fee | Office | 2021 | 1,038 | 3,879 | $121,723 | $80,071 | 65.8% |
| G0407 | Follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth | Office | 2021 | 20 | 37 | $3,277 | $1,940 | 59.2% |
| G0406 | Follow-up inpatient consultation, limited, physicians typically spend 15 minutes communicating with the patient via telehealth | Office | 2021 | 19 | 41 | $1,967 | $1,087 | 55.2% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2021 | 11 | 11 | $1,845 | $1,058 | 57.4% |
| Q3014 | Telehealth originating site facility fee | Office | 2020 | 908 | 3,388 | $106,315 | $70,763 | 66.6% |
| G0407 | Follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth | Office | 2020 | 22 | 34 | $3,029 | $1,924 | 63.5% |
| G0408 | Follow-up inpatient consultation, complex, physicians typically spend 35 minutes communicating with the patient via telehealth | Office | 2020 | 11 | 14 | $1,793 | $1,121 | 62.5% |
| G0406 | Follow-up inpatient consultation, limited, physicians typically spend 15 minutes communicating with the patient via telehealth | Office | 2020 | 11 | 11 | $531.74 | $339.33 | 63.8% |
About Dr. Andrew Rosenzweig, MD
Dr. Andrew Rosenzweig, MD is a Geriatric Psychiatry healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1942203690.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Rosenzweig, MD has received a total of $411,140 in payments from pharmaceutical and medical device companies, with $90,949 received in 2024. These payments were reported across 621 transactions from 4 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($318,880).
As a Medicare-enrolled provider, Rosenzweig has provided services to 2,807 Medicare beneficiaries, totaling 10,353 services with total Medicare billing of $214,464. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Psychiatry
- Other Specialties Geriatric Psychiatry, Geriatric Psychiatry
- Location Providence, RI
- Active Since 05/24/2005
- Last Updated 08/07/2018
- Taxonomy Code 2084P0805X
- Entity Type Individual
- NPI Number 1942203690
Products in Payments
- NUPLAZID (Drug) $291,247
- REXULTI (Drug) $87,151
- INGREZZA (Drug) $29,209
- DISEASE EDUCATION (Drug) $1,800
- Nuplazid (Drug) $1,500
- AUSTEDO (Drug) $196.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.